Aurum Bioscience is developing novel therapeutics for stroke patients

Globally, Stroke is a leading cause of death and disability. Only 5-10 % receive treatment and therefore, Acute Ischaemic Stroke is an unmet medical need.

Aurum’s patented ABL 101 platform technology represents a paradigm shift in stroke management.